Bioanalysis, biomarker assay development, validation and sample analysis.
Drug development and manufacturing for biologics and small molecules, with integrated services from preclinical, clinical to commercial.
Best-in-class drug discovery products and services to identify and develop life-changing therapies.
Global insourcing solutions delivering on-site scientific and laboratory services.
Delivering safety, efficacy, biomarker, and pathology services, through a global network of CAP accredited laboratories.
Solutions from discovery through commercialisation.
With facilities in Europe, North America and Asia, we support clients in the pharma, diagnostics, food, agriculture, biotechnological and research markets.
Comprehensive BioPharma Product Testing: a leader in testing biologics, CGT, nucleic acid therapies, and small molecules from early developm…
With over 40 years of expertise and capabilities, Eurofins Medical Device Services offers comprehensive solutions across the entire medical…
Stefano Gatti, Stefano.Gatti@bpt.eurofinseu.com; Leonela Tita Gallo, Leonela.TitaGallo@bpt.eurofinseu.com; Eurofins Regulatory & Consultancy Services Italy
With the introduction of European Regulation 2017/745 and 2017/746, focus on the usability of medical devices and IVD devices has increased due to these newly introduced, specific requirements. Usability can be considered a part of the more general risk assessment of medical devices. A Usability Evaluation is intended to identify and minimise use errors and thereby reduce use-related hazards to an acceptable level. A comprehensive approach to usability assessment involves several crucial phases and follows the reference standards IEC 62366-1 and IEC 62366-2:
Possible documents that comprise a usability file in compliance with IEC 62366-1 and IEC 62366-2 include: User Interface Specification, Usability Risk Assessment, and in the case of Formative Evaluation, the Formative Plan and Report and the Summative Plan and Report.
Regarding legacy devices, Annex C of IEC 62366-1 presents an alternative process to evaluate the usability of medical devices. Annex C of IEC 62366-1 significantly streamlines the process for evaluating usability, enabling manufacturers to utilise post-market data for unmodified aspects of the design to determine the presence of use errors, use-related hazards, and appropriate mitigation measures without the need for a validation test.
Eurofins Regulatory and Consultancy Services Italy can support manufacturers in planning a usability evaluation, both in terms of documentation and activities to be performed, in accordance with IEC 62366.